Tuesday, January 15, 2013

Major Revenue Losses From Patent Expirations Forces Big Pharma Companies to Look to the Biotech Industry for Replacements

Recent analyst upgrades and articles like this have provided a boost for Arena Pharmaceutical shares.

http://finance.yahoo.com/news/major-revenue-losses-patent-expirations-132000024.html

See disclaimers in the side bar.  This is not an endorsement for any company, or investment in any company.

Disclosure:  the author and family members are long shares of ARNA.  The author has no position in VVUS.

No comments:

Post a Comment